Member Info for Moneymunch

All good things....confirmation on receipt of Grant funding will be very well received, patent updates and progress on the rest of the pipeline at anytime, including Proof of Concept on the Dog Trial and JV/Licensing deal with their Vet Partner. Gla holders:-)

The trial aims to demonstrate proof of concept in dogs, replicating promising results previously seen in mice. “It worked like magic in mice. We reasonably think that it will work likewise in dogs,” Leire stated. Unlike mice, however, dogs share environmental conditions with humans, making them a more relevant model for translation into human therapies.

"So far, results have exceeded expectations!!! Gla :-)

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s upcoming clinical trial application in Europe for its MASH (metabolic dysfunction-associated steatohepatitis) therapy, GF-1002.

Leire explained that Genflow is prioritising the European Medicines Agency over the FDA as it seeks clinical trial authorisation (CTA) for its GF-1002 programme. He emphasised the importance of this milestone in building company value, stating: “To have proof of efficacy in humans is super important for us to move as fast as possible to clinical trial authorisation.”

The company is working with Belgian-based CDMO Exothera on the CMC part of the filing, and Leire said results so far have exceeded expectations. He also highlighted the dual-CRO strategy involving Physiogenex and Accelera to address both early and late-stage MASH models. This approach aims to provide flexibility when engaging with regulators about the most effective path forward.

In a second update, Leire said the protocol for Genflow’s GF-1004 dog trial has been amended. The changes relate to the infusion rate of the gene therapy, intended to ensure consistency and future usability by private veterinarians. This is seen as a key step toward a potential partnership with an animal health company, which would bring non-dilutive funding to the business.

Leire also mentioned supportive market tailwinds from upcoming FCA regulatory changes.

The Dog Trial’s PoC was iniated in March according to today's RNS, and so early positive results, could indeed lead to a timely JV, in the coming months. Gla ;-)

6/1/25

Dog Aging (GF-1004): We are initiating a life extension clinical trial for aging dogs in collaboration with our contract research partner, Syngene. This six-month study will assess the potential of a veterinary version of our gene therapy to extend both the health span and lifespan of dogs. We expect to complete the full analysis of the trial by the end of 2025. Based on the outcomes, we may explore partnership opportunities or licensing agreements with veterinary specialty pharmaceutical companies.

14th October 2024

"There's a very large appetite from the veterinary industry for life extension for our dog companions. Therefore, we'll provide proof of concept. We're starting this very soon, and once this proof of concept is finished, that should trigger an out-licensing deal with our partner in veterinary. "

Exciting times Porter, and plenty more to come , Genflow's current bargain basement low offers a rare opportunity for exponential UPside!!! Gl :-)

Hopefully 1p plus on its way, and sub 1p assigned to history...On and UP!!! Gla holders:-)

Nice one Porter, "clinical readiness acceleration", brings us one step closer to a potential JV/Commercial licensing deal, and given Physiogenex high profile partners, it's more than conceivable that one of the Major Pharma's are doing their due diligence. Gl ;-)

Clinical Readiness Acceleration

GENFLOW BIOSCIENCES PLC

Released 07:00:12 24 July 2025

RNS Number : 3206S

Genflow Biosciences PLC

24 July 2025

24 July 2025

Genflow Biosciences Plc

Clinical Readiness Accelerates Across Genflow Biosciences Lead Programs

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to report key preclinical activities in two of its lead programs.

GF-1002

In preparation for a submission for European Clinical Trial Authorisation (CTA), the EU's regulatory equivalent to the U.S. FDA's IND process, Genflow is continuing to advance key development activities. To support this process, the Company has initiated Chemistry, Manufacturing, and Controls (CMC) work in collaboration with its CDMO partner, Exothera, to ensure clinical supply production meets Good Manufacturing Practice (GMP) standards. In parallel, pivotal efficacy studies are underway with Genflow's independent CRO partners, Physiogenex and Accelera, evaluating GF-1002 in both early and advanced stages of MASH.

GF-1004

Genflow has submitted a first protocol amendment to its ongoing proof-of-concept clinical trial in aged dogs to clarify the administration of its investigational product, GF-1004. The amended protocol now specifies the intravenous (IV) dose rate to ensure consistent and controlled delivery, minimizing the risk of infusion-related adverse events and reinforcing patient safety. This randomized, controlled trial initiated in March in collaboration with the renowned CRO, Syngene is designed to evaluate the safety and efficacy of Genflow's proprietary SIRT6-centenarian gene therapy in addressing age-related decline in dogs.

Dr. Eric Leire, CEO of Genflow, commented: "This update reflects the growing maturity of our pipeline and our continued commitment to advancing science-backed therapies in healthy aging. The combination of expected non-dilutive funding, strategic partnerships, and supportive regulatory tailwinds puts Genflow in a strong position to accelerate both our programs."

The following deal was announced April 2024, and so something similar for Genflow's Sirt6 Mash/Liver program more than possible. Gla :-)

German pharma group Boehringer Ingelheim has struck an up to $1bn partnership with a UK biotech to develop treatments for chronic liver disease that aim to harness the organ’s capacity to regenerate.

Under the drug discovery partnership, Ochre Bio will receive $35mn in upfront and near-term payments, rising to more than $1bn in payments and royalties if treatments are successfully brought through clinical trials. It is a similar milestone-based structure to many partnerships in the pharmaceutical industry.

About time too!!! Long overdue but most welcome and hopefully much more UPside to come even without news, now the selling looks to be done. Not sure who had all those shares to sell but Aberdeen Angus were reported to be holding 2.6%, then the was the 62.5m Eric parted with to facilitate the £435k institutional investment and the 41.5m from the £500k subscription!!!??? All in the mix regardless and so now every chance Genflow has a clear runway for take off. Multiple newsflow stacking UP, patent news, non-dilutive grant funding news from the €4m grant, , Proof of Concept update on the Dog trial, €700k from the €1.5m towards R&D for Sarcopenia with Revatis, further positive news from the FDA for the upcoming Mash/Liver trial, progress and maybe a commercial partner on Sirt6/Glaucoma news, Orphan Drug Status for the Werner Syndrome program, to name but a few, and the chances of Major Pharma flexing their muscles, couldn't be higher. Genflow Biosciences, the potential bargain of the century and current bargain basement low!!! Gla holders...Excitement building!!! :-)

Given Genflow's cutting edge science, Gene Therapy and AVV delivery systems, backed up by very strong intellectual property patents in place , and the compelling nature of SIRT6's influence and importance in multiple therapeutic actions , diseases and aging, then every chance a Major Pharma could make an early move. In Eric we trust!!! Gla holders:-)

"There's a very large appetite from the veterinary industry for life extension for our dog companions. Therefore, we'll provide proof of concept. We're starting this very soon, and once this proof of concept is finished, that should trigger an out-licensing deal with our partner in veterinary. "

Proof of Concept on the Dog Trial, which commenced early this year could land at anytime. Eric had stated PoC could be the catalyst for a commercial deal with their Vet Partner, and was expected to take around 6 months. Gla holders:-)

The trial aims to demonstrate proof of concept in dogs, replicating promising results previously seen in mice. “It worked like magic in mice. We reasonably think that it will work likewise in dogs,” Leire stated. Unlike mice, however, dogs share environmental conditions with humans, making them a more relevant model for translation into human therapies.

Onwards and UP!!! Multiple positive newsflow stacking UP!!! Gla holders :-)

$1.2 Billion UPfront payment and $800m milestone payments on promising Phase 2 data for Mash/Liver.

Genflow's upcoming MASH trial is already planned to commence in Phase 2 , i believe. Gla holders:-)

GSK's Strategic Move into Liver Disease Therapeutics: A Pivotal Bet on Efimosfermin and Future Growth https://share.google/TKLA9zgL3I3S7s30T

Cash is King y, and so the market needs reaffirmation the €4m grant is still on its way. An additional €700k is also expected soon from the €1.5m grant awarded April 2024, and so along with the £1m cash raised in the last few months, Genflow's financial position is better than most small cap biotechs and are advancing their clinical programs as planned. News on the ongoing Dog trial and rest of the pipeline along with patents and grant funding etc could drop at anytime , and so the current bargain basement low offers tremendous UPside potential. Gla holders:-)

0

Genflow Confirms Progression of Grant

GENFLOW BIOSCIENCES PLC

Released 07:00:07 17 July 2025

RNS Number : 3831R

Genflow Biosciences PLC

17 July 2025

17, July 2025

Genflow Biosciences Plc

Genflow Confirms Approximately €4M Grant Support from Wallonia Region; GF-1002 Program Progressing without Interruption

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to reaffirm the previously announced award of approximately €4 million in non-dilutive financial support from the Wallonia Region of Belgium, supporting the development of its lead gene therapy candidate, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH). Read the RNS announcing this grant here.

The support package spans a three-year development program, aligned with Genflow's existing clinical roadmap. All project-related expenses incurred in 2025 will be considered eligible. While initial disbursement is pending the completion of standard administrative procedures on the government's side, Genflow has taken proactive steps to ensure the continuity of its GF-1002 program and confirms that progress remains on track with no delays to planned research or development activities.

Dr. Eric Leire, CEO of Genflow, commented: "We greatly appreciate the continued support from the Wallonia Region. The €4 million in non-dilutive funding represents a significant endorsement of our science and our strategy. We remain fully focused on advancing GF-1002 through the next stage of development and have ensured that operations proceed uninterrupted as the program moves forward."

Ditto Porter, Multiple positive newsflow stacking UP!!! Game changing news at anytime. Gl ;-)

All in the mix regardless, over 41m bought yesterday and 12m plus today. Gl :-)

Could be the Saudi, his 4.45% declaration back in May , must be around 27m, apart from Eric, no one else holds that many apart from the Institutional investors £435 & the £500k share subscription. Better out now imho and just need Eric to deliver a run of good news. Gla ;)

0

Eric's latest interview, well worth a listen, highlighting the importance of worldwide patents in place and multiple therapeutic targets towards Business Development, ie commercial licensing deals and partnerships with Major Pharma. Amazing potential and prospects. Gla ;-)

Genflow CEO on manufacturing deal, IP wins & dog study update

Published: 17 Jun 2025

CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about multiple recent developments across the company's programs. He highlighted a new manufacturing agreement with CER Groupe, which strengthens Genflow's gene therapy manufacturing capabilities and supports the company's access to research grants in Belgium. "We are lucky to have the possibility to find good quality partners in Belgium," Leire stated.

The company has also made notable progress in intellectual property, securing patent protection in the United States, Europe, and Japan for its Non-Alcoholic Steatohepatitis (NASH) program. Leire explained that these patents enable Genflow to pursue business development opportunities with pharmaceutical partners, offering non-dilutive funding options amid challenging capital markets.

On the clinical front, Genflow selected Exothera as its CDMO after successful large-scale manufacturing tests, which Leire said produced unexpectedly strong yields. This supports faster and more efficient clinical trial preparations while potentially lowering therapy costs.

Leire also provided an update on Genflow's dual gene therapy approach for sarcopenia. The company successfully achieved dual gene expression, which may enhance treatment potency and demonstrates Genflow's capabilities in complex gene therapy design.

Finally, Leire discussed ongoing dog studies in Morocco, which may lead to partnerships in animal health and generate further non-dilutive funding through upfront payments.

Genflow CEO on manufacturing deal, IP wins & dog study update | LSE:GENF, OTCQB:GENFF htTps://share.google/5KuxInroSiiYKioKm